vs
Side-by-side financial comparison of Day One Biopharmaceuticals, Inc. (DAWN) and HERON THERAPEUTICS, INC. (HRTX). Click either name above to swap in a different company.
HERON THERAPEUTICS, INC. is the larger business by last-quarter revenue ($40.6M vs $39.8M, roughly 1.0× Day One Biopharmaceuticals, Inc.). HERON THERAPEUTICS, INC. runs the higher net margin — -7.3% vs -49.6%, a 42.3% gap on every dollar of revenue. On growth, HERON THERAPEUTICS, INC. posted the faster year-over-year revenue change (-0.5% vs -57.6%).
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medic...
DAWN vs HRTX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.8M | $40.6M |
| Net Profit | $-19.7M | $-3.0M |
| Gross Margin | — | 72.6% |
| Operating Margin | -60.9% | 0.1% |
| Net Margin | -49.6% | -7.3% |
| Revenue YoY | -57.6% | -0.5% |
| Net Profit YoY | -153.3% | -180.6% |
| EPS (diluted) | $-0.19 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $40.6M | ||
| Q3 25 | $39.8M | $38.2M | ||
| Q2 25 | $33.9M | $37.2M | ||
| Q1 25 | $30.8M | $38.9M | ||
| Q4 24 | — | $40.8M | ||
| Q3 24 | $93.8M | $32.8M | ||
| Q2 24 | — | $36.0M | ||
| Q1 24 | $0 | $34.7M |
| Q4 25 | — | $-3.0M | ||
| Q3 25 | $-19.7M | $-17.5M | ||
| Q2 25 | $-30.3M | $-2.4M | ||
| Q1 25 | $-36.0M | $2.6M | ||
| Q4 24 | — | $3.7M | ||
| Q3 24 | $37.0M | $-4.8M | ||
| Q2 24 | — | $-9.2M | ||
| Q1 24 | $-62.4M | $-3.2M |
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 68.8% | ||
| Q2 25 | — | 73.5% | ||
| Q1 25 | — | 78.3% | ||
| Q4 24 | — | 74.9% | ||
| Q3 24 | — | 71.2% | ||
| Q2 24 | — | 70.8% | ||
| Q1 24 | — | 75.6% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | -60.9% | -10.7% | ||
| Q2 25 | -103.1% | -4.4% | ||
| Q1 25 | -133.5% | 8.1% | ||
| Q4 24 | — | 10.2% | ||
| Q3 24 | 31.6% | -13.6% | ||
| Q2 24 | — | -17.9% | ||
| Q1 24 | — | -13.8% |
| Q4 25 | — | -7.3% | ||
| Q3 25 | -49.6% | -45.8% | ||
| Q2 25 | -89.4% | -6.4% | ||
| Q1 25 | -117.0% | 6.8% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | 39.5% | -14.8% | ||
| Q2 24 | — | -25.6% | ||
| Q1 24 | — | -9.1% |
| Q4 25 | — | $-0.01 | ||
| Q3 25 | $-0.19 | $-0.10 | ||
| Q2 25 | $-0.29 | $-0.02 | ||
| Q1 25 | $-0.35 | $0.01 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | $0.38 | $-0.03 | ||
| Q2 24 | — | $-0.06 | ||
| Q1 24 | $-0.72 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $451.6M | $28.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $450.9M | $14.3M |
| Total Assets | $513.8M | $255.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $28.6M | ||
| Q3 25 | $451.6M | $43.1M | ||
| Q2 25 | $453.1M | $16.5M | ||
| Q1 25 | $473.0M | $19.3M | ||
| Q4 24 | — | $25.8M | ||
| Q3 24 | $558.4M | $25.7M | ||
| Q2 24 | — | $18.4M | ||
| Q1 24 | $317.9M | $20.4M |
| Q4 25 | — | $14.3M | ||
| Q3 25 | $450.9M | $14.9M | ||
| Q2 25 | $460.8M | $-27.3M | ||
| Q1 25 | $479.5M | $-28.5M | ||
| Q4 24 | — | $-33.7M | ||
| Q3 24 | $555.5M | $-40.0M | ||
| Q2 24 | — | $-37.9M | ||
| Q1 24 | $296.8M | $-33.8M |
| Q4 25 | — | $255.9M | ||
| Q3 25 | $513.8M | $248.9M | ||
| Q2 25 | $519.0M | $232.1M | ||
| Q1 25 | $534.4M | $235.8M | ||
| Q4 24 | — | $233.1M | ||
| Q3 24 | $600.8M | $220.8M | ||
| Q2 24 | — | $218.1M | ||
| Q1 24 | $326.6M | $217.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $-9.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-9.2M | ||
| Q3 25 | $-5.8M | $1.3M | ||
| Q2 25 | $-24.8M | $-10.9M | ||
| Q1 25 | $-59.0M | $-8.9M | ||
| Q4 24 | — | $-11.8M | ||
| Q3 24 | $50.8M | $3.4M | ||
| Q2 24 | — | $-4.6M | ||
| Q1 24 | $-49.7M | $-9.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-24.8M | $-11.1M | ||
| Q1 25 | $-59.3M | $-9.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $50.0M | $2.9M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -73.2% | -29.8% | ||
| Q1 25 | -192.8% | -23.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | 53.4% | 9.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 1.0% | 0.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -3.37× | ||
| Q4 24 | — | -3.22× | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
HRTX
| CINVANTI | $22.9M | 56% |
| ZYNRELEF | $12.5M | 31% |
| Aponvie | $3.8M | 9% |
| SUSTOL | $1.3M | 3% |
